Morinidazole is a nitroimidazole antimicrobial agent currently under investigation for treating anaerobic bacterial infections, such as those associated with appendicitis. As a member of the nitroimidazole… Read more
















Morinidazole is a nitroimidazole antimicrobial agent currently under investigation for treating anaerobic bacterial infections, such as those associated with appendicitis. As a member of the nitroimidazole class, it exerts its therapeutic effect by disrupting microbial DNA synthesis. This category features a comprehensive range of reference standards, including the active pharmaceutical ingredient, its known impurities, related enantiomers, and specific metabolites like glucuronides. Pharmaceutical laboratories utilize these high-quality compounds for essential analytical testing, enabling robust impurity profiling and method validation during drug development. Additionally, the availability of stable isotope-labelled compounds supports precise quantification in complex biological matrices, facilitating accurate pharmacokinetics and metabolic studies. By providing access to these critical materials, researchers can ensure compliance with quality control protocols throughout the lifecycle of the drug and support the advancement of clinical investigations for this antimicrobial treatment.